| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.049 | 0.8 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.8 |